Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations

Journal of Investigative Dermatology

Volumn 114, Issue 1, 2000, Pages 28-33

  Newton Bishop, Julia A ^a,d   Wachsmuth, Rachel C ^a   Harland, Mark ^a   Bataille, Veronique ^b   Pinney, Elizabeth ^a   Mack, Patricia ^a   Baglietto, Laura ^c   Cuzick, Jack ^a   Bishop, D Timothy ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

CDKN2A; Genetics; Melanocytic nevi; Melanoma

Indexed keywords

ARTICLE; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; GERM LINE; HUMAN; HUMAN TISSUE; MELANOMA; MULTIGENE FAMILY; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

EID: 0034076515     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00823.x     Document Type: Article

References (31)

1. Augustsson A, Stierner U, Rosdahl I, Suurkula M: Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 71:518-524, 1990
2. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J:. The p16-cyclin D/CDK4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483, 1996
3. Bataille V, Newton-Bishop J, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, Cuzick J. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 73:1605-1611, 1996
4. Bataille V, Grulich A, Sasieni P, et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 77:505-510, 1998
5. Bergman W, Palan A, Went LN: Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome. Ann Hum Genet 50:249-258, 1986
6. Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM: Systemic cancer and the FAMMM syndrome. Br J Cancer 61:932-936, 1990
7. Bishop DT, Easton DF: Frequency of familial melanoma and MLM2 gene. Lancet 345:581-582, 1995
8. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome-9p melanoma susceptibility locus (mlm). Cancer Res 54:6041-6044, 1994
9. Carey WP, Thompson CJ, Jr, Synnestvedt MA, Guerry D, Halpern A IV, Schultz D, Elder DE. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 74:3118-3125, 1994
10. Clark WH Jr: Human cutaneous malignant melanoma as a model for cancer. Cancer Metastasis Rev 10:83-88, 1991
11. Clark WH, Reimer RR, Greene MH, Asnworth AM, Masrangelo MJ. Origin of familial malignant melanoma from hereditable melanocytic lesions: the BK mole syndrome. Arch Dermatol 114:732, 1978
12. Cottingham RW, Jr, Idury RM, Schaffer AA: Faster sequential genetic linkage computations. Am J Hum Genet 53:252-263, 1993
13. Dracopoli NC, Fountain JW. CDKN2 mutations in melanoma. Cancer Surv 26:115-132, 1996
14. Foulkes W, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20, 1997
15. Goldstein A, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH, Tucker MA. Sun-related risk factors in melanoma prone families with CDKN2 mutations. J Natl Cancer Inst 90:709-711, 1998
16. Halpern AC, Guerry DP, Elder IV, DE, Clark WH, Synnestvedt M, Jr, Norman S, Ayerle R: Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. Arch Dermatol 127:995-999, 1991
17. Harland MH, Meloni R, Gruis N, et al: Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067, 1997
18. Harrison SL, MacLennan R, Speare R, Wronski I: Sun exposure and melanocytic naevi in young Australian children. Lancet 344:1529-1532, 1994
19. Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH: Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 51:45-55, 1991
20. Kefford RF, Newton-Bishop JA, Bergman W, Tucker MA: Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma. J Clin Oncol 17:3245-3251, 1999
21. Kraemer KH: Dysplastic nevus syndrome and cancer risk-response. J Am Acad Dermatol 5:850-851, 1987
22. Lynch HT, Fusaro RM: Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6:127-131, 1991
23. Newton JA: Familial melanoma. Clin Exp Dermatol 18:5-11, 1993
24. Newton JA, Bataille V, Griffiths K, et al: How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 29:989-996, 1993
25. Newton Bishop JA, Bataille V, Pinney E, Bishop DT. Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 4:199-206, 1994
26. Norris WA: A case of fungoid disease. Edinb Med Surg J 16:562-565, 1820
27. Richard MA, Grob JJ, Gouvernet J, Culat J, Normand P, Zarrour H, Bonerandi JJ: Role de L'Exposition Solaire sur les Naevus Melanocytaires Benins. Ann Dermatol Venereol 121:639-644, 1994
28. Risch N: Segregation analysis incorporating linkage markers. I. Single-locus models with an application to type I diabetes. Am J Hum Genet 36:363-386, 1984
29. Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216, 1998
30. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JAA, Clark J, Hole DJ: Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J 292:1555-1560, 1986
31. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p161NK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996